{"filings":[{"id":95678,"accession_number":"0001213900-26-041522","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vicarious Surgical shareholders approve reverse stock split at ratio of 1:2 to 1:30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over 11.8M votes in favor, 49,675 against, 3,430 abstentions at April 8 special meeting.","Reverse split ratio range set at 1-for-2 to 1-for-30; final ratio to be set by Board.","Approximately 60.68% of total voting power present, constituting a quorum.","Amendment to Certificate of Incorporation approved to effect reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108907,"accession_number":"0001213900-26-025193","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Vicarious Surgical reports Q4 net loss $10.5M; NYSE delisting, now on OTCID","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP net loss $10.5M ($1.57/sh) vs $13.9M ($2.36/sh) YoY; FY2025 net loss $50.2M ($8.19/sh) vs $63.2M ($10.74/sh) YoY.","Total operating expenses FY2025 $50.0M, down 25% YoY; cash burn $45.1M below initial ~$50M guidance.","FY2026 cash burn guidance approximately $19 million, reflecting continued cost reduction.","NYSE delisted stock March 3, 2026 for market cap <$15M; company did not appeal; now trades on OTCID under RBOT.","Cash and investments $9.8M as of Dec 31, 2025; lower burn extends runway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108906,"accession_number":"0001213900-26-024707","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vicarious Surgical NYSE delisting; President and CTO take salary cuts","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NYSE commenced delisting proceedings on March 3, 2026; stock now quoted on OTC under RBOT.","President Adam Sachs salary reduced to ~$270,810 annual; CTO Sammy Khalifa to ~$318,600, eff. March 9.","Target bonus and severance still calculated on prior higher salaries; executives waive Good Reason claims.","Salary cuts described as voluntary; no changes to post-employment obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108905,"accession_number":"0001213900-26-023404","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Vicarious Surgical receives NYSE delisting notice; trading suspended, moves to OTCID","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE notified Vicarious Surgical on Mar 3, 2026 of delisting for falling below $15M avg mkt cap over 30 trading days.","Trading suspended after market close Mar 3, 2026; company evaluating whether to appeal within 10 business days.","Common stock expected to commence quotation on OTCID tier on Mar 4, 2026 under symbol RBOT.","Delisting may reduce liquidity, market price, and ability to raise equity financing.","OTC markets significantly more limited than NYSE; company provides no assurance of continued trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108904,"accession_number":"0001213900-26-010807","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vicarious Surgical amends CEO severance, enters CFO severance agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Stephen From severance without cause: 1 yr base salary + pro-rata bonus + 12 mos COBRA.","CEO change-in-control severance: 2x base (12 mos) + pro-rata bonus + 24 mos COBRA + full equity vesting.","CFO Sarah Romano new severance: without cause = 6 mos base salary + pro-rata bonus + 6 mos COBRA.","CFO change-in-control: 2x base (6 mos) + pro-rata bonus + 12 mos COBRA + full equity vesting.","Severance payments conditional on signing separation agreement with release and covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108903,"accession_number":"0001213900-26-002973","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vicarious Surgical shareholders approve exercise of Oct 2025 warrants for 2.3M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held Jan 9, 2026; quorum of 78.18% of total voting power present.","Proposal approved with 14,991,093 votes For, 23,052 Against, 2,894 Abstentions.","Warrants issued Oct 7, 2025, exercisable for up to 2,300,000 shares of Class A common stock.","No other matters were submitted to a vote at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125367,"accession_number":"0001213900-25-122267","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["1.01","3.01","8.01","9.01"],"status":"ready","headline":"Vicarious Surgical guides FY2026 cash burn ~$35M (improved from $45M); NYSE to delist warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2026 cash burn guidance of ~$35M, a $10M improvement over the recently updated $45M 2025 guidance.","Additional cash needs beyond existing resources to achieve design freeze on Vicarious Surgical system are ~$25M.","Design freeze targeted by year-end 2026; cost reductions from headcount and consulting partially offset by strategic outsourcing.","NYSE to delist and immediately suspend trading in the Company's warrants (RBOT.WS) due to abnormally low price levels. No appeal.","Entered into ATM agreement with H.C. Wainwright for potential sale of up to ~$2.3M of common stock (based on Form S-3 limitation); 3% commission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125366,"accession_number":"0001213900-25-117558","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vicarious Surgical cuts 2025 cash burn outlook to ~$45M, improves by $5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Full-year 2025 cash burn guidance improved to ~$45M from prior $50M, reflecting cost management.","Company plans to provide 2026 cash burn guidance before year-end as part of operational reset.","Board reduced size from nine to seven; Beverly Huss and Randy Clark resigned effective Dec 1, 2025.","Victoria Carr-Brendel appointed Compensation Committee Chair; Fuad Ahmad and Joseph Doherty join committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125365,"accession_number":"0001213900-25-109214","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vicarious Surgical reports Q3 2025 net loss of $11.1M, down from $17.1M year-over-year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total operating expenses fell 35% to $11.5M from $17.8M in Q3 2024","GAAP net loss per share was $1.86 vs $2.90 in prior year quarter","Cash and investments $13.4M as of Sept 30, 2025; cash burn $10.5M in Q3","Company raised $5.9M in registered direct offering in October 2025","Full year 2025 cash burn guidance of approximately $50M"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125364,"accession_number":"0001213900-25-097471","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Vicarious Surgical prices $5.9M registered direct offering and private placement at $5.10/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering comprises 1,150,000 shares (or pre-funded warrants) and Series A & B warrants for up to 2,300,000 shares at $5.10 exercise price.","Gross proceeds ~$5.9M before fees; expects to close on October 9, 2025.","Series B warrants include a call provision tied to $5.10 stock price and $100K daily volume milestones.","Common warrants exercisable only after stockholder approval; company must seek approval within 120 days of closing.","Proceeds earmarked for working capital, capex, and R&D; Lake Street Capital Markets is placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142081,"accession_number":"0001213900-25-091651","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vicarious Surgical appoints Joseph Doherty as Chairman of the Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Doherty appointed Chairman effective Sept 25, 2025; he joined the Board in June 2025.","Doherty serves on Compensation Committee and chairs Nominating and Corporate Governance Committee.","Background includes President of Scapa Healthcare, Olympus Surgical Technologies America, and 24 years at Johnson & Johnson.","Currently CEO of Worcester City Campus Corporation, a not-for-profit supporting the University of Massachusetts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142080,"accession_number":"0001213900-25-090683","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vicarious Surgical completes controlled builds; on track for production-equivalent system by mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Controlled builds completed in April and August 2025 under full QMS, demonstrating reproducibility and scalability.","System functionality increased from 49% (June) to 63% (Sept 2025); on path to 100% by mid-2026.","Launch indication is ventral hernia repair; 66% of US ventral hernias are still performed open (Fry et al. 2024).","Targeting clinical readiness by year-end 2026 and human clinical trials in 2027 to support De Novo submission.","IP portfolio includes 160 patents (50 granted/allowed, 110 pending) covering core innovations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142079,"accession_number":"0001213900-25-088203","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Donald Tang resigns; Victoria Carr-Brendel joins audit committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donald Tang resigned from the board effective September 12, 2025, not due to any disagreement.","Victoria Carr-Brendel appointed to the Audit Committee in connection with Tang's departure.","No changes reported to other board committees or officer roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142078,"accession_number":"0001213900-25-085274","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vicarious Surgical updates investor presentation; targets ventral hernia repair, reaches 63% system functionality","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First build under control completed April 2025; second build completed August 2025 demonstrating scalability.","System functionality progressed from 49% (June) to 63% (September) toward 100%.","Next milestone: Production Equivalent System by mid-2026; Design Lock by year-end 2026.","Targeting 5.6M annual US abdominal procedures; 82% still non-robotic; initial focus on ventral hernia repair.","IP portfolio includes 43 granted/allowed patents and 87 pending, totaling 130 protections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142077,"accession_number":"0001213900-25-074974","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vicarious Surgical Q2 net loss narrows to $13.2M; CEO transition to Stephen From","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $13.2M ($2.23/share) vs. $15.2M ($2.59/share) in Q2 2024.","Operating expenses fell 24% YoY to $13.5M; R&D $9.1M, G&A $4.1M, S&M $0.3M.","Cash and investments $24.0M; Q2 cash burn $13.4M; FY2025 cash burn guidance ~$50M.","Adam Sachs becomes President; Stephen From appointed CEO effective August 12, 2025.","Non-GAAP adjusted net loss $13.3M ($2.23/share) vs. $16.8M ($2.86/share) year ago."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142076,"accession_number":"0001213900-25-070028","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vicarious Surgical appoints Stephen From as CEO, Adam Sachs becomes President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen From appointed CEO effective Aug 7, 2025; also joins Board.","Co-founder Adam Sachs transitions from CEO to President, remains on Board.","From receives $500k base salary, 50% target bonus, and 297,600-share option grant.","From previously CEO of Aruna Bio and Kiora Pharmaceuticals; 20+ yrs healthcare leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142075,"accession_number":"0001213900-25-063296","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["3.01","4.01","9.01"],"status":"ready","headline":"Vicarious Surgical's NYSE compliance plan accepted; auditor changed to Cherry Bekaert","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NYSE accepted compliance plan to regain $50M min market cap within 18 months; RBOT now trades with '.BC' indicator.","Dismissed Deloitte & Touche as independent auditor; no disagreements but material weaknesses in internal controls existed.","Appointed Cherry Bekaert as new auditor for fiscal year 2025, effective July 7, 2025.","Listing continues on NYSE during cure period; quarterly compliance reviews by NYSE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160051,"accession_number":"0001213900-25-059237","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Vicarious Surgical elects Fuad Ahmad and Joseph Doherty to board; Ric Fulop departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Fuad Ahmad (former CFO of Iridex, Mitek, Vaxart) and Joseph Doherty (CEO Worcester City Campus, former Olympus/J&J) elected at annual meeting.","Ric Fulop left the board effective June 27, 2025 after 5 years of service.","Stockholders approved amendment to 2021 Equity Incentive Plan, increasing share reserve by 311,046 shares.","Board adopted amended non-employee director compensation policy; new Product Committee chair retainer $14,250, member $5,500 annually.","All nine director nominees were elected; Deloitte & Touche LLP ratified as independent auditor for fiscal 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160050,"accession_number":"0001213900-25-042203","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vicarious Surgical Q1 2025: GAAP net loss $15.4M; FY cash burn guided ~$50M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $15.4M ($2.60/shr) vs $17.0M ($2.90) Q1 2024; adjusted net loss $15.3M ($2.58/shr).","Operating expenses $15.7M, down 2% YoY; R&D $9.4M, G&A $5.3M, S&M $1.0M.","Cash and investments $37.4M at March 31, 2025; Q1 cash burn $11.7M.","Full-year 2025 cash burn guidance approximately $50 million.","CEO says company is 'just a few quarters away' from first clinical patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160049,"accession_number":"0001213900-25-031124","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Vicarious Surgical receives NYSE delisting notice for low market cap and equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["30-day avg market cap ~$47.4M and stockholders' equity $46.7M as of Dec 31, 2024.","Company has 45 days to submit a compliance plan; 18-month cure period available.","Common stock will trade under RBOT with '.BC' designation until compliance restored.","Notice does not impact business operations or SEC reporting obligations.","Company considering options to regain compliance with NYSE standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178384,"accession_number":"0001013762-25-001611","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vicarious Surgical President Randy Clark resigns, appointed to Board effective April 25","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["President Randy Clark will resign effective April 25, 2025, and be appointed to the Board pending conflict checks.","Clark oversaw product development, operations, clinical regulatory, quality, and HR as President.","CEO Adam Sachs said transition retains Clark's strategic insights while evolving leadership for capital needs.","Clark implemented personnel realignment, streamlined processes, and formalized workflows to position for growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178383,"accession_number":"0001213900-25-024548","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vicarious Surgical reports FY2024 GAAP net loss $63.2M; sets 2025 cash burn guidance $50M; appoints new CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 GAAP net loss $63.2M ($10.74/share), adjusted net loss $63.3M ($10.75/share); Q4 GAAP net loss $13.9M.","Cash and investments $49.1M at Dec 31, 2024; 2024 cash burn of $49.1M met ~$50M guidance.","2025 cash burn guidance ~$50M; Version 1.0 system integration complete, progressing toward first clinical use.","Appointed Sarah Romano as CFO effective April 1, 2025; expanded hospital partnerships with LSU Health, Temple Health, University of Illinois Health."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178382,"accession_number":"0001213900-25-023441","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vicarious Surgical Appoints Sarah Romano as CFO Effective April 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sarah Romano named CFO and Treasurer, effective April 1, 2025; succeeds prior CFO? Not disclosed.","Base salary $435,000; target annual bonus 40%; receives stock option for 55,000 shares with 25% vesting at 1 year.","Romano previously CFO of Entero Therapeutics (Nasdaq: ENTO) and Kiora Pharmaceuticals (Nasdaq: KPRX).","Press release cites approaching first clinical use cases in 2025 as key milestone for financial strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178381,"accession_number":"0001213900-25-014890","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"COO John Mazzola to retire April 1, 2025; responsibilities to President Randy Clark","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Mazzola to retire as COO effective April 1, 2025, after nearly 40 years in healthcare.","Responsibilities will transition to Company President Randy Clark upon effective date.","Mazzola instrumental in manufacturing, quality control, and supply chain improvements.","Company positions for first clinical use cases and pivotal trial; no immediate impact on operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178380,"accession_number":"0001213900-25-005036","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vicarious Surgical enters consulting agreement with former CFO William Kelly through 2028","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Kelly departed as CFO; consulting from Jan 2, 2025 to Dec 31, 2028.","Consulting fee: $10,000/month from Jan 2 to June 30, 2025, then hourly rate.","Outstanding stock options and RSUs continue vesting until June 30, 2025 only.","Agreement includes confidentiality, non-solicitation, and customary terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195036,"accession_number":"0001213900-24-106503","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vicarious Surgical CFO William Kelly resigns effective Jan 2, 2025; succession search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Kelly steps down as CFO after nearly 4 years (since Jan 2021) to pursue other opportunities.","Departure effective January 2, 2025; Kelly to assist with transition and expects to sign consulting agreement.","Company has initiated a CFO succession process and will update as appropriate.","CEO Adam Sachs thanked Kelly for his contributions; Kelly expressed confidence in company's future."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195035,"accession_number":"0001213900-24-096820","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vicarious Surgical Q3 net loss $17.1M; cash $60.9M; on track for system milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $17.1M ($2.90/share); adjusted net loss $17.0M ($2.87/share), improved from $20.4M loss YoY.","Operating expenses $17.8M, down 17% YoY; R&D $10.8M, G&A $5.7M, S&M $1.2M.","Cash and investments $60.9M at Sept 30; Q3 cash burn $12.4M.","Reaffirms full-year 2024 cash burn guidance of ~$50M.","CEO expects Version 1.0 system integration milestone within weeks, first clinical patient in less than a year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211326,"accession_number":"0001213900-24-067689","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vicarious Surgical Q2 net loss $15.2M; cash burn $10.9M, reiterates FY2024 ~$50M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $15.2M ($2.59/sh) vs $15.3M ($3.62/sh) in Q2 2023; adjusted net loss $16.8M ($2.86/sh).","Operating expenses $17.7M, down 17% YoY; R&D $10.9M, G&A $5.6M, S&M $1.2M.","Cash and investments $73.2M as of June 30, 2024; Q2 2024 cash burn $10.9M.","Reaffirmed full-year 2024 cash burn guidance of approximately $50 million.","Partnered with LSU Health New Orleans as fifth U.S. hospital system; V1.0 integration milestone on track for fall 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229932,"accession_number":"0001213900-24-052876","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["3.03","5.02","5.03","5.07","9.01"],"status":"ready","headline":"Vicarious Surgical shareholders approve 1-for-30 reverse stock split, effective June 12, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse stock split at ratio of 1-for-30 effective June 12, 2024.","Class A shares reduced from ~156.8M to ~5.2M; Class B from ~19.6M to ~654k.","Warrants exercisable for ~921,620 shares at $345.00 per share post-split; CUSIP changed.","2021 Equity Incentive Plan amended to increase authorized shares by 5M pre-split (166,666 post-split).","All seven director nominees elected: Adam Sachs, Sammy Khalifa, Victoria Carr-Brendel, Ric Fulop, David Ho, Beverly Huss, Donald Tang."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229931,"accession_number":"0001213900-24-051236","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vicarious Surgical announces 1-for-30 reverse stock split to comply with NYSE minimum share price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio set at 1-for-30, approved by shareholders at June 10, 2024 annual meeting.","Effective 4:15 p.m. on June 12, 2024; shares to trade on NYSE post-split under RBOT starting June 13.","Class A shares reduced from ~156.8M to ~5.23M; Class B from ~19.6M to ~654k. No fractional shares.","Warrants adjusted: exercise price goes from $11.50 to $345.00 per share; shares issuable reduced proportionally.","Purpose: to increase per-share price and regain compliance with NYSE minimum share price listing requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229930,"accession_number":"0001213900-24-037162","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vicarious Surgical reports Q1 2024 net loss of $17.0M; cash burn guidance unchanged at $50M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $17.0M ($0.10/sh) vs $26.9M ($0.21) YoY; adjusted net loss $15.1M ($0.09).","Operating expenses fell 28% to $16.1M from $22.3M; R&D $10.0M, G&A $5.0M, S&M $1.1M.","Cash & investments $84.1M; Q1 cash burn $14.1M; FY 2024 cash burn guidance reaffirmed at ~$50M.","Completed spring cadaver lab; refining V1.0 system ahead of final integration in fall 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248392,"accession_number":"0001213900-24-019553","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vicarious Surgical Q4 2023 GAAP net loss $13.1M; 2024 cash burn guided ~$50M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 GAAP net loss $13.1M ($0.06/sh); adjusted net loss $14.6M ($0.07/sh), improving from $19.9M ($0.16/sh) in Q4 2022.","Full year 2023 GAAP net loss $71.1M ($0.49/sh); adj net loss $76.3M ($0.52/sh); cash burn $63.4M met objective.","Cash and investments $98.2M at year-end; 2024 cash burn guidance narrowed to ~$50M.","Signed fourth major hospital partnership with Intermountain Health; total partner hospitals exceed 250.","V1.0 system on track for spring cadaveric testing; integration expected fall 2024; appointed Randy Clark President."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248391,"accession_number":"0001213900-24-019546","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Executive Chairman David Styka resigns from Vicarious Surgical board, effective Feb 29, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Styka notified Board on Feb 27 of his resignation as executive chairman and director, effective Feb 29.","Resignation is not due to any disagreement with the company's operations, policies, or practices.","No replacement for Styka has been announced; CEO Adam Sachs remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248390,"accession_number":"0001213900-24-007204","cik":1812173,"company_name":"Vicarious Surgical Inc.","ticker":"RBOT","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vicarious Surgical appoints Randy Clark as President; Adam Sachs remains CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Clark appointed President effective Jan 29, 2024; Sachs steps down as President, continues as CEO.","Base salary $500,000; annual bonus target 50% of salary; eligible for 1,000,000 share option.","Clark previously Global President of Health Solutions at Flex Ltd. (FLEX) and 15 yrs at Olympus.","Role created as Vicarious Surgical prepares for finalization of V1.0 system this fall.","Clark will oversee product development, operations, clinical, regulatory, and HR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6839251.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}